Aurinia Pharmaceuticals Inc (AUPH)

[Zeppo]

I agree with you on ramping up a potential buy-out price a bit. Why? I just watched the interview with the BMY CEO. He outlined the product categories that were in early stages of clinical trials. Those trials are, collectively, going to cost billions. He also noted 85 ongoing collaborations with other biotech/pharma concerns. Many of those alliances also will cost a lot of money, because BMY, with its deep pockets, will be funding clinical trials. Yes, AUPH is off the beaten path for BMY, but BMY may not be able to afford to let go of a potential revenue stream of this magnitude from a company with an approved product that will no longer cost time and resources for more trials.